4820 Emperor Boulevard
658 articles with IQVIA
The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
IQVIA OPE is a SaaS patient engagement solution that bridges the gap between life sciences companies and patients
IQVIA Consumer Health announces its unique global technology and analytics suite to support the self-care and wellness industry from product concept to consumer use
IQVIA™ (NYSE:IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE).
The first Enterprise Quality Management Solution in the industry with expanded capabilities for European Union Medical Device Regulation regulations and compliance
The offer is for approximately 0.51 percent of the common shares outstanding.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2019 Global Healthcare Conference in New York, NY on Wednesday, September 4, 2019 at 9:40 a.m. ET.
IQVIA™ (NYSE:IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform.
IQVIA expects to fund the Repurchase with cash on hand and borrowings from its revolving credit facility.
IQVIA™ (NYSE:IQV) today announced that a new Life Science Strategy Group (LSSG) report named IQVIA the market leader in real world data and real world evidence services.
IQVIA™ announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation, Research & Development Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.
IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €720,000,000 in aggregate principal amount of senior notes due 2028.
IQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance
IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended June 30, 2019.
IQVIA Awarded Frost & Sullivan’s Life Sciences Product Leadership Award for Its Advanced Quality Management Technology Solution
IQVIA™ (NYSE:IQV) today announced it has received the Frost & Sullivan’s 2018 Global Enterprise Quality Management Solutions for Life Sciences Product Leadership award.
IQVIA Holdings Inc. (“IQVIA™”) (NYSE: IQV) has been named to the Forbes 2019 list of America’s Best Employers for Women
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its second-quarter 2019 financial results before the market opens on Wednesday, July 24, 2019.
Lannett Company, Inc. announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg.
Disruptive tech simplifies patient engagement and amplifies patients’ voices to advance outcomes for life science companies
Chiesi Group Selects IQVIA’s OCE Technology Platform to Develop a Customer Centric Ecosystem across the Organization
Leveraging innovative technology to orchestrate cross functional teamwork and multichannel interactions with external stakeholders
Clinical Ink’s Jonathan Andrus Invited to Speak at the Duke-Margolis Center for Health Policy Public Meeting
Clinical Ink is pleased to announce that Jonathan Andrus, chief business officer at Clinical Ink, has been invited to be a panelist in a public meeting hosted by the Duke-Margolis Center for Health Policy on July 17, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with the FDA, will discuss opportunities to improve the implementation of risk-based monitoring (RBM) in clinical investigations.